4-butyrolactone has been researched along with physostigmine in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andén, NE; Wachtel, H | 1 |
| Fukuchi, I; Kawashima, K; Kawashima, Y; Kinoshita, K; Matsuoka, Y; Yamamura, M | 1 |
| Hoffman, RS; Howland, MA; Nelson, LS | 1 |
| CHEMNITIUS, KH; DOSS, M; KARL, M | 1 |
4 other study(ies) available for 4-butyrolactone and physostigmine
| Article | Year |
|---|---|
Increase in the turnover of brain dopamine by stimulation of muscarinic receptors outside the dopamine nerve terminals.
Topics: 4-Butyrolactone; Animals; Apomorphine; Aromatic Amino Acid Decarboxylase Inhibitors; Atropine; Atropine Derivatives; Brain; Corpus Striatum; Dopamine; Hydrazines; Male; Nerve Endings; Norepinephrine; Oxotremorine; Physostigmine; Rats; Receptors, Cholinergic; Receptors, Muscarinic | 1977 |
Effect of TA-0910, a novel thyrotropin-releasing hormone analog, on in vivo acetylcholine release and turnover in rat brain.
Topics: 4-Butyrolactone; Acetylcholine; Animals; Brain; Cerebral Cortex; Cholinesterase Inhibitors; GABA Modulators; Hippocampus; Male; Microdialysis; Nootropic Agents; Physostigmine; Rats; Rats, Sprague-Dawley; Thyrotropin; Thyrotropin-Releasing Hormone | 1996 |
Central nervous system depression after ingestion of RenewTrient.
Topics: 4-Butyrolactone; Antidotes; Central Nervous System; Cholinesterase Inhibitors; Depression, Chemical; Humans; Physostigmine | 1999 |
[Inhibition of cortisone inactivation in rat liver homogenate by butenolide and butenolide-dipyrine combinations].
Topics: 4-Butyrolactone; Aminopyrine; Analgesics; Analgesics, Non-Narcotic; Antipyretics; Cortisone; Liver; Physostigmine | 1960 |